Safety, PK, and DDI of PTI-801 in Healthy Volunteers and CF Patients

Phase 1, randomised, double-blind trial of Posenacaftor in cystic fibrosis (CF) (13 arms), sponsored by Proteostasis Therapeutics. Primary endpoints: Safety and tolerability measured by adverse events, labs, ECGs, physical exams, vital signs at 21 days, Apparent terminal half-life at 72 hours and 5 more. Started Apr 2017; status: completed.